Psyence Biomedical Buys PsyLabs Shares for $3.5M
Ticker: PBMWW · Form: 6-K · Filed: Sep 5, 2025 · CIK: 1985062
Sentiment: neutral
Topics: investment, subsidiary, material-agreement
TL;DR
Psyence Biomedical just bought $3.5M in Psyence Labs shares on Aug 15, 2025. Big move for psychedelics.
AI Summary
On August 15, 2025, Psyence Biomedical Ltd. entered into a subscription agreement with Psyence Labs Ltd. (PsyLabs). Under this agreement, PsyLabs will issue 1,750 shares to Psyence Biomedical Ltd. at a price of $2,000 per share, totaling $3,500,000.
Why It Matters
This transaction represents a significant investment by Psyence Biomedical Ltd. into its subsidiary, Psyence Labs Ltd., potentially indicating a strategic move to consolidate or expand operations within the psychedelic medicine sector.
Risk Assessment
Risk Level: medium — The filing details a material agreement for share issuance, which could impact ownership structure and future financial performance, but lacks details on the strategic rationale or broader market conditions.
Key Numbers
- $3.5M — Transaction Value (Total amount Psyence Biomedical Ltd. is investing in Psyence Labs Ltd.)
- 1,750 — Shares Acquired (Number of shares of Psyence Labs Ltd. purchased by Psyence Biomedical Ltd.)
- $2,000 — Price Per Share (The cost for each share of Psyence Labs Ltd.)
Key Players & Entities
- Psyence Biomedical Ltd. (company) — Filer and investor
- Psyence Labs Ltd. (company) — Subsidiary and issuer of shares
- August 15, 2025 (date) — Date of subscription agreement
- $2,000 (dollar_amount) — Price per share
- 1,750 (number) — Number of shares issued
- $3,500,000 (dollar_amount) — Total value of the transaction
FAQ
What is the strategic purpose behind Psyence Biomedical Ltd.'s acquisition of 1,750 shares in Psyence Labs Ltd. for $3,500,000?
The filing does not explicitly state the strategic purpose, but it details the transaction where Psyence Biomedical Ltd. agreed to purchase 1,750 shares of Psyence Labs Ltd. at $2,000 per share on August 15, 2025.
What is the total value of the subscription agreement between Psyence Biomedical Ltd. and Psyence Labs Ltd. as of August 15, 2025?
The total value of the subscription agreement is $3,500,000, based on 1,750 shares issued at $2,000 per share.
When was the subscription agreement entered into between Psyence Biomedical Ltd. and Psyence Labs Ltd.?
The subscription agreement was entered into on August 15, 2025.
What is the price per share for the transaction between Psyence Biomedical Ltd. and Psyence Labs Ltd.?
The price per share is $2,000.
Does Psyence Biomedical Ltd. file annual reports under Form 20-F or Form 40-F?
Psyence Biomedical Ltd. files annual reports under Form 20-F.
Filing Stats: 367 words · 1 min read · ~1 pages · Grade level 11.7 · Accepted 2025-09-05 16:05:13
Key Financial Figures
- $2,000 — ares of PsyLabs at a price per share of $2,000, for an aggregate purchase price of $3,
- $3,500,000 — 000, for an aggregate purchase price of $3,500,000. The closing of the transaction was con
Filing Documents
- ea0255928-6k_psyence.htm (6-K) — 13KB
- ea025592801ex99-1_psyence.htm (EX-99.1) — 93KB
- 0001213900-25-085011.txt ( ) — 107KB
From the Filing
OF FOREIGN PRIVATE ISSUER UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of September 2025 Commission File Number: 001-41937 Psyence Biomedical Ltd. (Translation of registrant’s name into English) 121 Richmond Street West Penthouse Suite 1300 Toronto, Ontario M5H 2K1 (Address of principal executive office) Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F. Form 20-F Form 40-F Entry into Material Agreement On August 15, 2025, Psyence Biomedical Ltd. (the “ Company ”) entered into a subscription agreement (the “ Agreement ”) with Psyence Labs Ltd. (“ PsyLabs ”). Pursuant to the Agreement, PsyLabs agreed to issue to the Company 1,750 shares of PsyLabs at a price per share of $2,000, for an aggregate purchase price of $3,500,000. The closing of the transaction was conditioned upon the receipt of required approvals by the parties thereto. On September 1, 2025, the transaction closed. PsyLabs is a privately-held company specializing in the production of psychedelic active pharmaceutical ingredients and extracts for research, clinical trials, and drug development. The Company previously acquired a minority interest in PsyLabs, as disclosed in the Company’s annual report on Form 20-F. Certain executives, including the Executive Chairman, the Chief Financial Officer and the General Counsel, and an independent director, of the Company provide consulting services to PsyLabs in exchange for consulting fees. Such individuals, together with the Company’s Chief Executive Officer, own less than 5% of the outstanding shares of PsyLabs in the aggregate. Certain of these individuals are also members of the board of directors of a wholly-owned subsidiary of PsyLabs. 1 EXHIBIT INDEX Exhibit No. Description 99.1 Form of Subscription Agreement, dated August 15, 2025, by and between Psyence Biomedical Ltd. and Psyence Labs Ltd. 2 SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. Dated: September 5, 2025 Psyence Biomedical Ltd. By: /s/ Jody Aufrichtig Name: Jody Aufrichtig Title: Executive Chairman 3